Analysts of the nation's healthcare system say long-term care is the crisis of the 21st century and 3 out of 5 people will need it, while 2 out of 5 will require nursing home facilities.

According to Frank N. Darras, widely regarded as one the nation's leading disability and long term care insurance lawyers, the number of Long Term Care policyholders has increased 21 percent annually and now there are approximately six million LTC policies in the United States

Surgeons have developed a new technique to fix an uncommon but serious foot deformity that occurs less than 10 percent as often as clubfoot does. Known as Congenital vertical talus (CVT), or "rocker-bottom flat foot," about 1 in 10,000 babies are born with the condition. If they grow up without treatment, they end up walking on the inside of their ankle instead of the bottom of their foot.

The condition causes pain and disability, but now Dr. Matthew B. Dobbs, a pediatric orthopedic surgeon at Washington University School of Medicine in St. Louis, says he has a cure

New research suggests that all pregnant women with clinical depression should receive adequate treatment immediately as it is the leading cause of premature births.

The stress hormones or corticotropin releasing-hormone (CRH), play an important role in the development of the unborn baby. If a woman gets depressed during pregnancy, the CRH hormone shoots up which leads to triggering labor

An Australian study suggests women suffering from arthritis to invest time in exercising to increase their chances of staying pain-free from the disease. According to a recent study published in the journal Arthritis Research and Therapy, even exercising as little as one hour and 15 minutes a week now can make a difference.

AP quotes lead author Kristiann Heesch from the University of Queensland, Australia as saying, "I don't think the results are suggesting that you should just become this maniac exerciser. What it does suggest is that just adding some walking and moderate activity to your life can make a big benefit

The U.S. Food and Drug Administration (FDA) approved the first drug of its kind (Soliris [generic name, eculizumab]) to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).

Only about one in a million persons are diagnosed with PNH. However, this rare disorder that usually develops in adults is characterized by abnormally developed red blood cells that can lead to disability and premature death